Researchers at the La Jolla
Institute for Allergy and Immunology in the US have entered into the final
stage of developing the much-awaited vaccine, confirming significant arterial
plaque reduction in concept testing in mice.
As part of the study, Klaus Ley, a pioneer
in the field of vascular immunology, used two mouse peptides for validating his
He found that vaccinated mice had
about 40 percent less arterial plaque when compared to the mice that didn't
receive the vaccine.
"Many research studies over
the last 15 years have demonstrated inflammation's critical role in heart
disease. By creating a vaccine to reduce inflammation in the arteries, we hope
to significantly lessen the accompanying plaque buildup," Ley said.
The vaccine is said to be
functioning more like the desensitisation process used in allergy shots. Allergy shots are designed to teach the individual's
immune system to endure the allergen.
The vaccine could also target
strokes, which are a product of plaque buildup in arteries.
Klaus Ley collaborated with fellow scientist
from La Jolla Institute Alessandro Sette, and Dr Tse of Wayne State University,
Michigan, According to the researchers the next step would be to test promising
candidate peptides in specially engineered mice with an immune system closer to
The scientists said that the
vaccine could begin human clinical trials in as little as three years.
The study was published in the journal Frontiers in